The chimeric antigen receptor T (CAR-T) cell therapy is a new treatment for a variety of cancers. The idea is to take out the T-cells from the patient, and genetically engineer the cells to make them express a chimeric antigen receptor (CAR) recognizing a specific tumor-associated antigen (TAAs). As a result, the CAR-expressing T cells, when reintroduced into the patient's body, will target and eliminate the TAA-expressing tumor cells.
The CAR-T clinical trial in Hospital is for patients with B-cell acute lymphocytic leukemia（B-ALL）, B-cell lymphoma and multiple myeloma, who developed refractory or relapsed disease from chemotherapy.
Since 2015, we have completed about 300 CAR-T clinical trials for refractory relapsed B-ALL, B-cell lymphoma and multiple myeloma with excellent results. We summarized and published the first 51 cases in the Journal of Leukemia in 2017.
The overall complete remission rate has been more than 90%.
It approximately takes about 6-8 weeks for CAR-T clinical trial.
Although the complete remission (CR) rate of CAR-T treatment is high, the risk of relapse still present. Studies have been shown that bridging BMT after CAR-T for B-ALL could further increase the potential cure rate.
Blood and bone marrow transplantation is a special therapy for patients with certain cancers or other marrow diseases. A blood and bone marrow transplant involve taking cells that are normally found in the bone marrow, processing those cells, and giving them back either to the patient or to another person. The goal of blood and bone marrow transplantation is to transfuse healthy bone marrow cells into a person after their own unhealthy bone marrow has been eliminated. Blood and bone marrow transplantation has been used successfully to treat diseases such as leukemias, lymphomas, aplastic anemia, immune deficiency disorders, and some solid tumor cancers since 1968.
The following diseases are the ones that most commonly benefit from blood and bone marrow transplant:
• Severe aplastic anemia
• Multiple myeloma
• Immune deficiency disorders
hospitals has autologous transplant, allogeneic transplant, HLA matched unrelated transplant, haploidentical transplant, cord blood transplant and syngeneic transplant.
We have the best outcomes in blood and marrow transplant especially for haploidentical and unrelated matched donor BMT in the world. Moreover haplo-BMT in our hospital can achieve comparable outcomes with HLA-identical sibling transplantation.
Our disease-free survival（DFS）rate of BMT are about 80% at the first complete remission (CR1)，60%-70% at CR2, 40% at CR3/NR respectively.
It approximately takes about 3-6months for allogeneic blood and marrow transplant. The period of autologous blood and marrow transplant is much shorter. It approximately takes about 1-3 months.
we would like to provide streamlined access and individual support for our international patients. Our staff will be there to assist all patients during all phases of his / her care: For more detailed information, please click here-----